Defective Drugs:
Actos Linked to Bladder Cancer
Actos
An Actos bladder cancer warning was released by the FDA on June 15, 2011 to inform the public that patients taking the Type 2 diabetes drug (pioglitazone) for longer than a year may have an increased risk of developing bladder cancer. The agency made this announcement, linking Actos and bladder cancer, after it had reviewed data which showed that patients with the longest exposure to the drug were put at a greater risk of bladder cancer. In fact, the risk of Actos bladder cancer among these patients was reportedly as high as 40%.
If you were diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact, you may be entitled to compensation. To find out if you are eligible, complete our no cost, no obligation case review form today with the details of your Actos bladder cancer claim.
Actos and Bladder Cancer
In releasing the Actos bladder cancer warning, the FDA also cited data from a study conducted by the French National Health Insurance Plan. This study found that patients who had been exposed to the diabetes drug had a 22% increased risk of developing Actos bladder cancer. Additionally, in patients who had taken the drug for more than a year, the risk was reportedly as high as 34%. Patients who had taken a cumulative dose exceeding 28,000 milligrams had the highest risk (75%) for Actos bladder cancer. The possible risk of Actos bladder cancer was found primarily in men.
In light of this research, the Actos bladder cancer warning advised doctors not to prescribe Actos to patients with active bladder cancer or a history of the disease. It also warned that patients taking the drug should be on alert for signs which may indicate Actos bladder cancer, such as:
- Pain during urination
- Abdominal or back pain
- Blood in the urine
- Strong urge to urinate
Were you diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact? Fill out our free case evaluation form today to find out if you are eligible for an Actos bladder cancer lawsuit.
Actos Bladder Cancer Lawsuits
Because the manufacturer of the drug may have failed to warn patients about the possible Actos bladder cancer risk, patients who were diagnosed with cancer of the bladder after taking this medication may have legal recourse. Potentially, an Actos bladder cancer lawsuit would allow patients the opportunity to seek compensation for medical bills, pain and suffering and other damages resulting from their disease. If you or a loved one was diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact, complete our no risk, no cost case review today to find out if you may be eligible for an Actos bladder cancer lawsuit.